Skip to content
Screener

Charles River Laboratories CRL DSA — Total Revenue

Other segment segments

RMS
$209.48M-1.8%
Manufacturing
$188.1M-6.3%

Similar metrics at other companies

ImmunityBio, Inc. logo
IBRXOther revenues — Total Revenue
$39K+388%
PTH
PTHSNet product revenues — Total Revenue
$10.67M—
Life Time Group Holdings logo
LTHTotal center revenue — Total Revenue
$837.4M+13.8%
iRadimed logo
IRMDTotal devices revenue — Total Revenue
$15.39M+18.7%
Illumina logo
ILMNTotal product revenue — Total Revenue
$982M+7.7%
Globalstar logo
GSATTotal service revenue — Total Revenue
$60M-5.1%

Other financials

Income statement

See full
Revenue$1.0B-2.7%
Gross profit$349.0M-3.5%
Operating income$119.9M+19.7%
Net income-$1.5M-103%
EPS (diluted)-$0.03-103%

Balance sheet

See full
Cash & equivalents$240.6M+30.2%
Total debt$3.0B+8.1%
Total equity$2.8B-15.3%
Total assets$7.5B-0.4%

Cash flow

See full
Operating cash flow$179.7M-12.2%
CapEx$31.1M-11.9%
Free cash flow$148.6M-12.2%

Valuation

See full
Market cap$12.56B+70.1%
Enterprise value$15.36B+53.4%
P/S3.1×+1.3×

Profitability

See full
Gross margin84.7%—
Operating margin13%-2.4pp
Net margin-6%—
FCF margin9.3%-5.1pp

Returns & leverage

See full
Return on equity-7.7%—
Debt / equity1.1×+0.2×
Current ratio1.3×0.0×

Where this comes from

Reported directly by Charles River Laboratories in its filing.

Tagged under the XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax.

The source filing: Charles River Laboratories’s 10-Q, filed August 5, 2026.

Filed
Aug 5, 2026, 9:21 AM EDT
Fiscal quarter
Q2 FY2026
Calendar quarter
Q2 2026
Accession
0001100682-26-000118
Line itemThree Months Ended / June 27, 2026Three Months Ended / June 28, 2025Six Months Ended / June 27, 2026Six Months Ended / June 28, 2025
Service revenue$808,287$840,836$1,606,439$1,638,759
Product revenue195,791191,299393,469377,544
Total revenue1,004,0781,032,1351,999,9082,016,303
Costs and expenses
Cost of services provided (excluding amortization of intangible assets)552,007584,8761,160,9141,162,304
Cost of products sold (excluding amortization of intangible assets)88,69790,192180,956179,200
Selling, general and administrative228,897191,549388,319369,348
Amortization of intangible assets14,58965,38429,934130,648

Item 1. Financial Statements

FAQ

What is Charles River Laboratories's DSA — total revenue?
Charles River Laboratories (CRL) reported DSA — total revenue of $606.51M in Q2 2026.
How has Charles River Laboratories's DSA — total revenue changed year-over-year?
Charles River Laboratories's DSA — total revenue decreased by 1.9% year-over-year, from $618.03M to $606.51M.
What is the long-term trend for Charles River Laboratories's DSA — total revenue?
Over 2 years (2023 to 2025), Charles River Laboratories's DSA — total revenue has grown at a -4.2% compound annual growth rate (CAGR), from $2.62B to $2.4B.
What does DSA — total revenue mean?
Represents the total gross income generated by the Discovery and Safety Assessment segment from its core service offerings. This metric reflects the market demand for the segment's research and testing capabilities before accounting for any operational expenses.

Ask your AI about Charles River Laboratories's dsa — total revenue.

Connect your AI assistant and compare segments, right in your chat.

Connect your AI
Harbor at dusk
Claude